
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 or 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934**

For the month of April, 2019

Commission File Number: 001-38452

MEREO BIOPHARMA GROUP PLC

(Translation of registrant's name into English)

**4th Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Mereo BioPharma Group plc*("Mereo" or the "Company")***Notification of Director Dealing**

London, April 29, 2019 - Merco BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 29 April 2019, Peter Fellner, Chairman of Merco BioPharma, purchased 30,000 new ordinary shares in the Company at a price of GBP1.28 per share, as set out in the table below.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.

1	Details of the person discharging managerial responsibilities					
a)	Name	Peter Fellner				
2	Reason for the notification					
a)	Position/status	Chairman				
b)	Initial notification/ Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Mereo BioPharma Group plc				
b)	LEI	213800U8JQHJOS5AS09				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument and identification code	MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH				
b)	Nature of the transaction	PURCHASE OF ORDINARY SHARES				
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>GBP1.28</td><td>30,000</td></tr></table>	Price(s)	Volume(s)	GBP1.28	30,000
Price(s)	Volume(s)					
GBP1.28	30,000					
d)	Aggregated information: volume, Price	Aggregated volume: 30,000 ordinary shares Aggregated price: GBP1.28				

e)	Date of the transaction	2019-04-29
f)	Place of the transaction	AIMX

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 30, 2019

MEREO BIOPHARMA GROUP PLC

By: /s/ Charles Sermon

Name: Charles Sermon

Title: General Counsel
